Beazley, Other Insurers Duck Endo Trust’s Claims on Zantac Harm

Several excess insurers, including a unit of Beazley Plc, escaped a suit brought by a trust handling claims related to Endo International heartburn products as part of the drugmaker’s court-approved plan to exit Chapter 11 bankruptcy.

The US District Court for the Eastern District of Pennsylvania on Wednesday granted a motion to dismiss the trust’s claims against certain insurers that provided excess liability coverage to Endo for its ranitidine products, after the trust notified the court it wasn’t opposed to the insurers’ motion. The Food and Drug Administration requested the removal of ranitidine products—such as Zantac and generic versions—from the ...